Compare SGML & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGML | AAPG |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | Canada | China |
| Employees | N/A | 767 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2021 | N/A |
| Metric | SGML | AAPG |
|---|---|---|
| Price | $20.91 | $21.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $18.75 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 3.5M | 1.9K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $272.11 | $290.34 |
| Revenue Next Year | $36.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $20.11 |
| 52 Week High | $24.48 | $48.45 |
| Indicator | SGML | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 35.99 |
| Support Level | $18.96 | $20.11 |
| Resistance Level | $22.32 | $25.23 |
| Average True Range (ATR) | 1.81 | 0.53 |
| MACD | -0.37 | -0.24 |
| Stochastic Oscillator | 35.33 | 5.04 |
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds full interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil. Geographically, the company operates in Switzerland; United Arab Emirates; Singapore; and Republic of Korea, of which it derives maximum revenue from Switzerland.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.